

Enforcement Actions

8 March 2001

SFC Successfully Prosecutes Brightline Futures Company Limited and Mr Cai Yuan for Contravening the Securities (Disclosure of Interests) Ordinance

The Securities and Futures Commission (SFC) announced today that it had successfully prosecuted both Brightline Futures Company Limited (Brightline) and its director Mr Cai Yuan (Cai) under the Securities (Disclosure of Interests) Ordinance.

The case against Brightline related to its acquisitions and disposals of a total of 80 million and 44.472 million shares of Star Bio-Tech (Holdings) Limited (Star Bio-Tech) (previously known as Chung Hwa Development Holdings Limited) on four occasions during the period 18 January 2000 to 31 March 2000. Brightline, a substantial shareholder of Star Bio-Tech, failed to report to the Stock Exchange of Hong Kong its changes of interests in the shares of Star Bio-Tech within 5 days of its becoming aware of such changes. At the material time, Cai was the director of Brightline responsible for reporting the changes.

Ms Polly Lo, a Magistrate at Western Magistracy, fined Brightline and Cai of \$26,000 and \$5,000 respectively and ordered them to pay investigation costs of a total of \$29,707 to the SFC.

Page last updated: 7 November 2001

[主頁](#) ▶ [新聞稿及公布](#) ▶ [新聞稿](#) ▶ [執法消息](#)

證監會成功檢控中華前景控股有限公司及其董事蔡原違反《證券(披露權益)條例》

2001年3月8日

證券及期貨事務監察委員會(證監會)今天公布,本會已根據《證券(披露權益)條例》成功檢控中華前景控股有限公司(中華前景)及其董事蔡原(蔡氏)。

上述個案涉及中華前景在2000年1月18日至2000年3月31日期間,先後四次合共購入80,000,000股及沽售44,472,000股星光生物科技(控股)有限公司(前稱中華發展控股有限公司)(星光生物科技)的股份。中華前景身為星光生物科技的大股東,未有在發現其在星光生物科技股份的權益有所改變後的5天內,向香港聯合交易所作出有關的申報。在所有關鍵時刻,蔡氏都是中華前景的董事,並負責就有關的權益改變作出申報。

西區裁判法院盧恆福裁判官分別判處中華前景及蔡氏罰款26,000元及5,000元。此外,上述公司及人士亦被法院命令須向證監會支付合共29,707元的調查費用。

最後更新日期:2012年8月1日